No Data
Sector Update: Health Care Stocks Decline Late Afternoon
Sector Update: Health Care
UBS Initiates EnGene Holdings(ENGN.US) With Hold Rating, Announces Target Price $7
Express News | EnGene Holdings Inc : UBS Cuts to Neutral From Buy
Express News | EnGene Holdings Inc : UBS Cuts Target Price to $7 From $34
EnGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)
Wins333 : Thanks for the update, but market responses otherwise got be something hidden
Jaguar8 OP Wins333 : Nowadays, I notice that market reaction tends to be delayed
Wins333 Jaguar8 OP : Agreed bro, I think that’s deliberated. I will say you have a great sense